Top Three Skills: stem cell culture, PCR and cell-based assays
Job Description: The temporary Research Associate II position will be responsible for contributing to the development of novel stem cell therapies using cutting edge technologies in cell […
BioPhase Solutions specializes in recruiting top talented professionals for San Diego’s Scientific community. We are currently looking for a Lab Operations Support Manager to work for a leading San Diego biotechnology company.
Operations Support Man […
The Operations Support Manager is responsible for managing a San Diego, California laboratory and facility. This position will ensure processes and services are monitored for quality, cost effectiveness, and efficiency through conti […
Patent Prosecution Associate Attorney/Agent– Biotech. 2 – 5 Years of Experience. We have an urgent need for a Biotech Patent Prosecution Associate / Agent in…
From Morrison & Foerster – 31 Mar 2015 14:26:59 GMT
– View all San Diego jobs
Patent Prosecution Agent or Analyst – Electronics, Software & Telecommunications (EST) or Biotech – Entry Level. 0-1 Years of Experience….
From Morrison & Foerster – 31 Mar 2015 14:26:59 GMT
– View all San Diego jobs
Australian start-up, Sonoa Health, has today appointed a respected investment banker as CEO. His mission: bring an innovative product to market, secure strategic partnerships, and expand internationally
SAN FRANCISCO, March 31, 2015 /PRNewswire/ — Sonoa Health, a health tech startup based in Melbourne, Australia, has developed a world-first consumer health portal, Health&, which brings together data from online health records, medication prescriptions, wearable devices and more.
Today, the Company appointed respected investment banker John Stewart as its CEO, who brings to the table more than 18-years experience in investment banking and corporate advisory, which has included working closely with the biggest names in Silicon Valley in the US.
Sonoa Health’s Founder and Chair, Mr Bob Biddle, said Mr Stewart’s appointment is a significant achievement for the Company, which was officially founded four years ago and ramped up production for its consumer health portal early last year with more than 50 handpicked recruits. The portal will be launched later this year.
“We are in a very exciting phase of our development and John’s appointment is a testament to the quality of the company we’ve built and the talent we’ve attracted to drive its success. We are delighted to welcome him to the team,” said Mr Biddle.
“John has spent more than a decade in the heartland of digital health in Silicon Valley and will contribute invaluable perspectives to our business as we secure strategic business partnerships, raise capital, launch our product, and expand internationally.”
Sonoa Health’s new CEO isn’t hesitating to embrace the challenge.
“Sonoa Health presents a rare opportunity to work with the very best medical, creative and digital minds, and has enormous potential for global growth. After more than 18-years in banking, I am pretty comfortable navigating risk and reward – and I know we’re in for an exhilarating climb here,” said Mr Stewart.
Sonoa Health is taking an astute step forward in the highly saturated health tech market, by engaging the world’s most respected medical pioneers to drive the development of health technology and education resources.
“Our Health& portal is designed to provide an intelligent interface between doctors and consumers, which displays consumer health information in one place and helps them to proactively manage illness. It is supported by a search engine containing animated, illustrated and written health content, which is derived from evidence-based resources and designed to boost health literacy,” said Mr Biddle.
“The unique algorithms at the core of Health& power a reasoning engine, which brings the logic of a doctor’s brain online and delivers truly individualised health information to consumers. To achieve this, we’ve accessed the brightest brains and harvested their knowledge.”
The Company has engaged nine medical professors, who are all members of the Order of Australia, to head its Medical Advisory Board. In-house, there is a bright young team of doctors, writers, developers, animators, illustrators and an entrepreneurial leadership team too.
“It’s heartening to lead a brave and committed team of individuals, who are so focused on improving lives across the world. The launch of the Health& consumer portal later this year will signal a great achievement for Australia’s innovation sector,” said Mr Stewart.
Prior to joining Sonoa Health, Mr Stewart was a Managing Director at Gresham Partners, a Managing Director with Lazard in Australia and spent more than 11 years in the US in M&A roles with JPMorgan and Thomas Weisel Partners.He has also worked as an M&A lawyer with Fried Frank in New York and Corrs in Australia.
For more information about Health& visit www.healthand.com
To request an interview with Sonoa Health CEO, John Stewart, please contact Chief Communications Officer, Haley Price, on +61-423-139-163 email@example.com
Links & Resources:
* Photos of CEO John Stewart and the Sonoa Health team may be downloaded:
* A video showcasing the Health& consumer portal is available HERE – http://healthand.com/
* Further resources are available upon request
Visit the Sonoa Health corporate website [ http://corp.sonoahealth.com/ ]
SOURCE Sonoa Health
CARLSBAD, CA–(Marketwired – March 31, 2015) – International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based biotechnology company developing novel stem cell-based therapies and biom…
SAN DIEGO, March 31, 2015 /PRNewswire/ — Ajinomoto Althea, Inc. (“Althea”), a leading provider of biopharmaceutical contract development and manufacturing services, announced today that it has added two more top pharmaceutical companies to its growing list of partners in developing and manufacturing cGMP-produced crystal-based drug products using Althea’s Crystalomics® drug delivery technology. With these additional companies, a total of 4 out of 10 of the world’s top pharmaceutical companies have already signed agreements with Althea since Ajinomoto’s acquisition of Althea and the Crystalomics® technology. This proprietary Crystalomics® formulation technology is utilized to formulate and manufacture crystal suspensions of developed drug substance. Often, drug manufacturers encounter stability and delivery challenges for protein products including antibodies that require delivery at high concentration and low viscosity or must be administered frequently. Products formulated with the Crystalomics® technology can be delivered at low viscosity and high concentrations in a small volume. In addition, the Crystalomics® technology enables extended release of a week or more, transforming daily to weekly injections.
David Enloe, President and CEO of Althea, states, “We are very pleased to see a growing number of pharmaceutical companies implementing work with our Crystalomics® technology. We welcome the opportunity to support this growing list of partners by delivering regulatory compliant crystal suspension products that will overcome their high concentration delivery challenges. The Crystalomics® formulation technology has tremendous potential in drug development, promoting enhanced outcomes of drug treatments and improving compliance.”
Althea’s crystal suspension manufacturing services deliver a comprehensive set of service capabilities including Crystalomics® process development, in-process and release testing analytics, equipment qualification and validation, and complete cGMP bulk manufacturing fill and finish production.
About Ajinomoto Althea, Inc.
Althea is a fully integrated, contract development and manufacturing organization located in San Diego, CA providing clinical and commercial product development services. Althea offers cGMP drug product filling in both vials and syringes, and production of microbial-derived recombinant proteins and plasmid DNA. In conjunction with these manufacturing operations, Althea offers comprehensive development services including: upstream and downstream process development, analytical development, lyophilization cycle, complex formulation, product release and ICH-compliant stability testing. Althea’s formulation technology platform includes Crystalomics®, a proprietary technology that offers a formulation solution for large molecule products that must be delivered at high concentrations or as sustained release formulations. Althea also has an innovative and proven recombinant protein expression technology called Corynex® technology. For more information visit us at www.altheaCMO.com.
There is talk, and there is action. In the drive toward healthcare tailored for smaller and smaller groups of people, there was both last week, and both illustrated not just the promise of precision…
[[Click headline to continue reading.]]
CA-San Diego, As the only global provider of commercial solutions, Quintiles understands what it takes to deliver nationally and internationally. Our teams help biopharma get their medicines to the people who need them. We help customers gain insight a…